AI-generated from publicly available materials.The Ohio State University has unveiled Buckeye BioLaunch, an innovative initiative aimed at accelerating drug discovery through AI technology.
This program integrates clinical and genomic data with academic research, leveraging resources from the Ohio State Wexner Medical Center and its Comprehensive Cancer Center, as well as the Colleges of Medicine and Pharmacy. The overarching goal is to establish a robust pipeline for therapeutic development, fostering economic growth and job creation in Central Ohio.
Situated within the university's Innovation District, Buckeye BioLaunch will be spearheaded by Deanna L. Kroetz and Xiaolin Cheng. The initiative is set to support 10 to 20 AI-driven projects annually, covering the full spectrum of drug development—from target identification to clinical trials. Success will be gauged through various metrics, including patents and startup formations, with aspirations of positioning Ohio State as a leader in therapeutic innovation.
The initiative capitalizes on the transformative potential of AI in drug discovery, utilizing extensive clinical and genomic datasets from Ohio State Genomic Health. By combining these data resources with the university's expertise in drug development and clinical research, Buckeye BioLaunch aims to significantly enhance therapeutic advancements. This initiative is part of a broader strategy that includes faculty hiring in relevant fields and aligns with the university's AI(X) Hub for interdisciplinary AI research.